Efficacy of tetramethylpyrazine injection combined with butylphthalidein treatment of transient ischemic attack
- VernacularTitle:川芎嗪注射液联合丁苯酞治疗短暂性脑缺血发作的疗效观察
- Author:
Hao CUI
1
;
Huimin LU
;
Na LIU
Author Information
- Publication Type:Research Article
- Keywords: transient ischemic attack; ligustrazine; nerve function; butylphthalein; cerebral glucose metabolism; platelet activation
- From: Journal of Clinical Medicine in Practice 2024;28(2):32-37
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy of ligustrazine injection combined with butylphthalein in treatment of transient ischemic attack (TIA) and the its effects on cerebral glucose metabolism, platelet activation and immune inflammation reaction. Methods A total of 100 patients with TIA were selected and randomly divided into control group A (
n =33), control group B (n =33) and observation group (n =34). The control group A was given butylphthalide treatment, the control group B was given tetramethylpyrazine injection treatment, and observation group was given tetramethylpyrazine injection combined with butylphthalide treatment, three groups were treated for two weeks. The clinical efficacy, stroke risk (ABCD2 score), neurological function [National Institutes of Health Stroke Scale (NIHSS) score], cerebral glucose metabolism (KE value andTmax value), platelet activation [α-granular membrane protein-140 (GMP-140), P-selectin (CD62p) and platelet activating factor (PAF)], immunoinflammatory indexes [interleukin (IL)-17, IL-23 and high mobility group protein B1 (HMGB1)] and safety were compared among the three groups. Results The total clinical effective rate of the observation group was 97.06%, which was significantly higher than 75.76% of the control group A and 72.73% of the control group B (P < 0.05). After one week and two weeks of treatment, ABCD2, NIHSS scores,KE values andTmax values in the three groups were significantly lower than before treatment, and the observation group was significantly lower than the control group A and control group B (P < 0.05); the levels of CD62p, PAF, GMP-140, IL-17, IL-23 and HMGB1 in the three groups were significantly lower than before treatment, and the observation group was significantly lower than the control group A and control group B (P < 0.05). Conclusion Ligustrazine injection combined with butylphthalein in treatment of TIA can improve the cerebral glucose metabolism and nervous function of patients, reduce the risk of stroke, with high safety and significant efficacy, which may be related to the inhibition of platelet activation and immune inflammatory response.
